Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

AUA Abstract Roundup

May 6th 2013

The 108th AUA Annual Meeting held May 4-8 in San Diego, California, contained over 2,000 presentations focused on urologic medicine. This entry contains summaries of four abstracts focused on urothelial, testicular, and prostate cancer.

The Value of Office-Based Prescription Dispensing

May 3rd 2013

Steve Dobbs, the CEO of Urologic Specialists of Oklahoma, Inc, discusses the viability, legality, and successful implementation of an office-based medication-dispensing solution.

ODAC Votes Against Tivozanib in Renal Cell Carcinoma

May 2nd 2013

A single clinical trial was deemed insufficient to support approval of tivozanib for the treatment of patients with advanced renal cell carcinoma, according to a 13-1 vote by the FDA's Oncologic Drugs Advisory Committee.

Dr. Dreicer on an Alternate Sunitinib Schedule in mRCC

April 1st 2013

Robert Dreicer, MD, MS, from the Cleveland Clinic in Ohio, discusses a 2-weeks-on and 1-week-off (2/1) schedule of sunitinib for patients with metastatic renal cell carcinoma.

AGS-003 Vaccine Achieves Survival Benefits in mRCC

March 26th 2013

AGS-003, a personalized dendritic cell immunotherapy, demonstrated prolonged survival benefits in patients with metastatic renal cell carcinoma, with one-third of those who took the drug during a phase II trial still alive after nearly four years.

Studies Determine Smokers' Risks of Recurrence, Progression, and Survival in Bladder Cancer

March 20th 2013

An international group of investigators provided first-time evidence of the impact of smoking on outcomes in bladder cancer in results from two studies.

Blazing the Oregon Trail: Oregon Urology Institute Nurtures Its Position as a Urology Care Leader

March 19th 2013

An interview with Bryan Mehlhaff, MD, and retired physician Robert Litin, MD, about how Oregon Urology Institute is adapting its well-established practice to an ever-shifting healthcare landscape.

Dr. Hoffman on the Urologist's Influence on Treatment Choice

March 11th 2013

Karen E. Hoffman, MD, MHSc, MPH, from the MD Anderson Cancer Center, describes the diagnosing urologist's influence on the initial treatment selected for elderly men with favorable prostate cancer.

Dr. Robert Motzer Reviews the Phase III COMPARZ Study

March 5th 2013

Robert J. Motzer, MD, from Memorial Sloan-Kettering Cancer Center, discusses the COMPARZ trial that compared pazopanib to sunitinib as a first-line therapy for patients with metastatic renal cell carcinoma.

Dr. Gomella on the Value of a Multidisciplinary Cancer Center

February 27th 2013

Leonard G. Gomella, MD, discusses the benefits of the multidisciplinary center at Jefferson Kimmel Cancer Center.

Dr. Kamat on a Molecular Definition of BCG Failure

February 26th 2013

Ashish M. Kamat, MD, from MD Anderson Cancer Center, discusses enhancing clinical trial recruitment through a novel definition of BCG therapy failure in patients with nonmuscle invasive bladder cancer.

Targeted Therapies, Multidrug Regimens, and Standardized Drug Development Efforts Needed in Nonmuscle-Invasive Bladder Cancer

February 26th 2013

Collaborative and standardized efforts to develop and evaluate novel drugs are necessary to ultimately provide effective long-term treatment for nonmuscle-invasive bladder cancer.

Partial Nephrectomy Remains Underutilized, Despite AUA Endorsement

February 26th 2013

Although the 2009 AUA guidelines cite "compelling data" for consideration of nephron-sparing surgery in all patients, partial nephrectomy remains underutilized for small renal masses.

Dr. Deepak Kapoor on Integrated Urology Practices

February 21st 2013

Deepak A. Kapoor, MD, president of the Large Urology Group Practice Association, discusses the greater exposure to high-quality healthcare that is provided by the integration of ancillary services into community urology practices.

Dr. Galsky on a Post-Treatment Nomogram in Urothelial Cancer

February 20th 2013

Matthew D. Galsky, MD, from the Mount Sinai Medical Center Tisch Cancer Institute, discusses the development of a post-treatment prognostic model for patients with metastatic urothelial cancer.

Dr. Weiss on PPAR-Alpha as a Target in Kidney Cancer

February 19th 2013

Robert H. Weiss, MD, from the UC Davis Comprehensive Cancer Center, discusses peroxisome PPAR-alpha as a possible new treatment target for patients with renal cell carcinoma.

Dr. Huang Compares Surveillance and Treatment in Kidney Cancer

February 18th 2013

William C. Huang, MD, from the New York University Langone Medical Center, discusses findings from a SEER database analysis that compared surveillance to surgical resection in elderly patients with small renal masses.

PFS Not Significantly Better With First-Line Axitinib Versus Sorafenib in mRCC

February 16th 2013

Axitinib did not demonstrate superiority over sorafenib as first-line therapy for patients with metastatic renal cell carcinoma, on the endpoint of progression-free survival.

Tandems of Targeted Therapy No Better Than Bevacizumab Alone in Advanced Renal Cell Carcinoma

February 16th 2013

Combination targeted therapy did not significantly extend progression-free survival compared with single-agent bevacizumab in patients with advanced renal cell carcinoma.

Dr. Motzer Analyzes Overall Survival in the TIVO-1 Study

February 15th 2013

Robert J. Motzer, MD, from Memorial Sloan-Kettering Cancer Center, discusses the overall survival results from the phase III TIVO-1 study that compared tivozanib to sorafenib in patients with renal cell carcinoma.